In agreement, in our investigation, the antifibrotic role of nintedanib was indeed suggested by its capability to significantly reduce the production and release of TGFβ1 after 24 h of treatment in cultured MDMs from SSc-ILD patients compared to untreated cells. Here, TGFB1 is linked to systemic sclerosis.